Publications by authors named "Douglas Feltner"

Claim this Profile
P
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Mohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, Glenn J Hanna, Douglas E Laux, Douglas E Feltner

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
Gretchen Thomsen, Arthur H M Burghes, Caroline Hsieh, Janet Do, Binh T T Chu, Douglas E Feltner

Nat Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
John W Day, Richard S Finkel, Claudia A Chiriboga, Anne M Connolly, Thomas O Crawford, Douglas E Feltner

Lancet Neurol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas E Feltner

J Mark Access Health Policy· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
Samiah A Al-Zaidy, Stephen J Kolb, Linda Lowes, Lindsay N Alfano, Richard Shell, Douglas E Feltner

J Neuromuscul Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.
Omar Dabbous, Benit Maru, Jeroen P Jansen, Maria Lorenzi, Martin Cloutier, Douglas Feltner

Adv Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy.
Linda P Lowes, Lindsay N Alfano, W David Arnold, Richard Shell, Thomas W Prior, Douglas E Feltner

Pediatr Neurol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Omar Dabbous, Benit Maru, Jeroen P Jansen, Maria Lorenzi, Martin Cloutier, Douglas Feltner

Adv Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
Daniel C Malone, Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Douglas E Feltner

J Mark Access Health Policy· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.
Jared W Young, William Z Potter, Steve Riley, Geert J Groeneveld, Bruce J Kinon, Douglas E Feltner

Innov Clin Neurosci· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vocal acoustic biomarkers of depression severity and treatment response.
James C Mundt, Adam P Vogel, Douglas E Feltner, William R Lenderking

Biol Psychiatry· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD.
Suzanne M Sutherland, Lenard A Adler, Crystal Chen, Michael D Smith, Douglas E Feltner

J Clin Psychiatry· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.
John H Greist, Maria Liu-Dumaw, Edward Schweizer, Douglas Feltner

Int Clin Psychopharmacol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Douglas E Feltner, Maria Liu-Dumaw, Edward Schweizer, Robert Bielski

Int Clin Psychopharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid.
Douglas E Feltner, George Haig

J Psychopharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.
Louis S Matza, Robert Morlock, Chris Sexton, Karen Malley, Douglas Feltner

Int J Methods Psychiatr Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure.
Mohamed A Kamal, David E Smith, Jack Cook, Douglas Feltner, Allen Moton

J Pharm Sci· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.
Jonathan R T Davidson, Douglas E Feltner, Ashish Dugar

Prim Care Companion J Clin Psychiatry· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Valerie S L Williams, Robert J Morlock, Douglas Feltner

Health Qual Life Outcomes· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
R Bruce Lydiard, Karl Rickels, Barry Herman, Douglas E Feltner

Int J Neuropsychopharmacol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.
Douglas Feltner, Cheryl Hill, William Lenderking, Valerie Williams, Robert Morlock

J Psychiatr Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
Brian Corrigan, Douglas E Feltner, Daniele Ouellet, John L Werth, Allen E Moton

Br J Clin Pharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
Douglas E Feltner, Jane Harness, Jerri Brock, Angelo Sambunaris, Joseph C Cappelleri

CNS Neurosci Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis